103 CARNEGIE CENTER, PRINCETON, NJ
Shareholder votes
Announces First Quarter 2027 Financial Results, Provides Business Update
Other Events, Press Release
Announces 2026 Fiscal Year-End Financial Results, Provides Business Update Type A Meeting Scheduled with FDA to Potentially Clarify Path to NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA Resubmission for the Treatment of Patients with aSAH
Investor Presentation
Consulting Agreement with Ms. D'Andrea Following Departure
Provides Regulatory Update on New Drug Application for GTx-104
Q1
FY 2025
Q3
Amended Quarterly Report
Q2
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
S-8 POS